联系我们

Company Profile

ProteinT

A national high-tech enterprise dedicated to multi-omics research at the frontier of precision medicine. ProteinT leads the Tianjin Key Laboratory of Clinical Multi-omics, conducting integrated genomics, proteomics and metabolomics research alongside proprietary mass-spectrometry-based liquid biopsy technology. Our core team comes from Yale University, the U.S. National Institutes of Health and the National Center for Protein Sciences. Our R&D pipeline covers early screening, recurrence monitoring and companion diagnostics for liver, lung, gastric, esophageal, colorectal and pancreatic cancers, as well as pan-cancer and cardiovascular diseases. Backed by our proprietary Umbrella^TM clinical molecular database with over 100,000 clinical sample records, ProteinT is committed to continuously innovating medical technology and advancing its commercialization and clinical application to explore more possibilities for human health.

10W+

Clinical sample records
50%

PhD share in R&D team

mission

Mission

Keep creating market demand

Continuously advance medicine

Mission

mission

Keep creating market demand

Continuously advance medicine
Vision

vision

Setter of new standards in medical technology
Values

opinion

Gather excellence

Compose life

Founder
introduction

Founder

Li Jie

Distinguished expert introduced by Tianjin Medical University General Hospital; Director of the Tianjin Key Laboratory of Clinical Multi-omics.

Previously a researcher at the NIH National Institute of Neurological Disorders and Stroke, a researcher in the Department of Pathology at Yale University School of Medicine, and Director of the Biorepository at the Yale Cancer Center. His research focuses on individualized precision diagnosis and treatment through integrated multi-omics analysis of genomics, proteomics and metabolomics. In 2014, Dr. Li returned to China and founded ProteinT (Tianjin) Biotechnology Group, dedicated to translating multi-omics advances into clinical medicine. He has published more than 70 papers in journals including Science and Nature Genetics, holds over 60 international patents and software copyrights, and has led or undertaken more than 10 national and international research funding projects. He is a member of the American Association for Cancer Research and a member of the Glioma Committee of the Chinese Medical Doctor Association.

Milestones

2014

Founded ProteinT Biotechnology
Established the ProteinT clinical mass spectrometry laboratory
Participated in the Science & Technology Commission's major anti-cancer research program
2015

Certified as a Tianjin technology-based SME
Established a molecular diagnostics center in partnership with Tianjin Medical University General Hospital
2016

Recognized as a National High-Tech Enterprise
Founded Baikang Hexin Medical Laboratory, initiating independent clinical testing
2017

Applied the integrated gene–protein–metabolite “trinity” multi-omics technology to clinical practice
2018

Founded ProteinT NMR, expanding into chronic disease management services
Landed NMR lipid testing in China
2019

Established normal reference ranges for blood lipids in the Chinese population; cumulative sample testing exceeded 40,000 cases
2020

Approved as the Tianjin Key Laboratory of Clinical Multi-omics
2021

Breakthrough in mass-spectrometry-based liquid biopsy, enabling identification and quantification of 4,000+ blood proteins per sample within one hour
Clinical proteomics products for six major cancers translated; multiple products entered the regulatory filing process